Following priming in response to a B16-OVA tumor in the dermis, TRM cells that re-engaged their target antigen on melanocytes in the skin (gp100-specific) were present in far greater numbers than those that could not (OVA-specific) (111). This evidence concerns the gene PMEL and neoplasm.